At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 167 enrolled
Drug / intervention
AKB-9778 +1 moredrug
Likely dose
AKB-9778 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 (Razuprotafib)15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
In Brief
A Phase 2 clinical trial evaluating AKB-9778 and Placebo for Nonproliferative Diabetic Retinopathy. Completed, enrolled 167 participants across 53 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonproliferative Diabetic Retinopathy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
First PostedJun 2017
Primary CompletionJan 2019
Study CompletionFeb 2019
TodayJul 2026
First PostedJun 23, 2017
Enrollment StartJun 9, 2017
Primary CompletionJan 9, 2019
Study CompletionFeb 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.0 years ago
Interventions
AKB-9778drug
Subcutaneous AKB-9778 15mg
Placebodrug
Subcutaneous Placebo